Viking Therapeutics, Inc. (VKTX) · Oct 28, 2026 · Earnings
Miss — EPS $(1.55) vs ~$1.06 consensus
Viking’s third-quarter earnings missed consensus as spending accelerated, while VK2735 Phase 3 trials and cash resources remained on track.
Viking is a clinical-stage obesity biotech building VK2735 in both injectable and oral forms, with four registration studies now underway and additional maintenance-dosing work aimed at improving long-term treatment flexibility. The quarter missed on the scorecard, but the miss reflects investment rather than a new clinical setback. Viking reported a quarterly loss of $1.55 per share versus a published consensus near $1.06, with no revenue expected for a company that has no marketed products.
| Metric | Q3 2026 | Q3 2025 / expectation |
|---|---|---|
| Revenue | $0 | $0 expected |
| Net loss | $(183.2) million | $(90.8) million |
| Diluted loss per share | $(1.55) | $(0.81) prior year; ~$1.06 consensus |
| R&D expense | $166.8 million | $90.0 million |
| Cash, cash equivalents and short-term investments | $960 million | $706 million at Dec. 31, 2025 |
The core operating story is still advancing. Both VANQUISH Phase 3 studies continued on schedule, and the company still expects them to finish in 2027. 〔0〕 That matters because VK2735 remains the company’s central value driver, but this filing adds execution confirmation rather than a new efficacy readout; the oral SUNRISE Phase 3 start and the first maintenance-study results had already been announced before this release.
The pipeline is becoming broader, not yet de-risked. Viking has begun Part 2 of the maintenance study, testing oral, every-other-week, monthly, and placebo regimens, while VK3019’s first-in-human single-dose study is nearing completion. The company expects a four-week multiple-ascending-dose study of VK3019 to begin in the first quarter of 2027. These are meaningful development steps, but they remain future catalysts rather than proof that the Phase 3 program will succeed.
Funding materially extends execution capacity, with dilution and debt attached. Viking ended September with $960 million of cash, cash equivalents and short-term investments, supported by roughly $550 million of net financing proceeds. That gives the company resources to run multiple large trials and prepare commercial infrastructure, while the quarter’s 127.5 million shares outstanding versus 114.8 million at year-end and $250.7 million of convertible notes show that the runway was bought partly through equity issuance and added obligations.
The earnings miss is the main surprise, not the clinical update. R&D expense rose to $166.8 million from $90.0 million as Phase 3 trials, manufacturing, staffing, and related development work expanded. For a loss-making biotech, heavier spending can be strategically sensible, but versus consensus it still produced a wider-than-expected loss and leaves the business dependent on future VK2735 data.
Bottom line: Viking is spending aggressively to move VK2735 toward pivotal readouts, and the financing gives it room to do so. But against expectations, the quarter was a miss, while the favorable pipeline developments were mostly already known rather than newly delivered surprises.
ObesityWeek presentations, November 14–17
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!